Drug approved for symptomatic vitreomacular adhesion

Drug approved for symptomatic vitreomacular adhesion

(HealthDay)—Jetrea (ocriplasmin) has been approved by the U.S. Food and Drug Administration to treat an eye condition called symptomatic vitreomacular adhesion (VMA).

The condition affects the vitreous, which begins to separate from the macula. This can damage the macula, a key part of the eye's retina that's responsible for people being able to read, the FDA said Thursday in a news release.

Jetrea helps break down proteins that are responsible for VMA, preventing the need for surgery to control the condition, the agency said.

In a clinical study of 652 people, VMA resolved in 26 percent of those who took Jetrea, compared to 10 percent of cases that were resolved among those who took an inactive placebo.

The most common side effects of Jetrea were including: bleeding, pain, floaters, blurriness, vision loss, and swelling.

Jetrea is produced by ThromboGenics, based in Iselin, N.J.

More information: The FDA has more about this approval.

add to favorites email to friend print save as pdf

Related Stories

Vitreolytic ocriplasmin resolves vitreomacular traction

Aug 16, 2012

(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse ...

FDA approves drug to treat diabetic macular edema

Aug 13, 2012

The U.S. Food and Drug Administration today announced its approval of Lucentis (ranibizumab injection) for the treatment of diabetic macular edema, or DME, an eye condition in people with diabetes that causes blurred vision, ...

Glaucoma stent approved

Jun 26, 2012

(HealthDay) -- An ocular stent that's designed to reduce inner-eye pressure among people with mild or moderate open-angle glaucoma has been approved by the U.S. Food and Drug Administration.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

21 hours ago

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.